Any feedback?
Information on EC 2.4.2.10 - orotate phosphoribosyltransferase and Organism(s) Homo sapiens
for references in articles please use BRENDA:EC2.4.2.10Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
2.4.2.10 orotate phosphoribosyltransferaseIUBMB Comments
The enzyme from higher eukaryotes also catalyses the reaction listed as EC 4.1.1.23, orotidine-5'-phosphate decarboxylase.
Specify your search results
Word Map
- 2.4.2.10
- pyrimidine
- 5-fluorouracil
- thymidylate
- dihydropyrimidine
- uridine
- thymidine
- uracil
- colorectal
- dihydroorotase
-
pyre
-
fluoropyrimidine
-
4.1.1.23
- orotidine-5'-monophosphate
-
5-fluoroorotic
-
transcarbamoylase
-
5-fu-based
- leucovorin
-
phosphoribosylpyrophosphate
-
5-fluorouracil-based
-
5-fu-related
-
prototrophy
-
tegafur
- odcase
- dihydrouracil
-
succinate-grown
-
5-phosphoribosyl
- fdump
-
5-fu-resistant
- podospora
-
phosphoribosyltransferases
- 5-fluoro-2'-deoxyuridine
-
fluoropyrimidine-based
- ompdc
-
5-phosphoribosyl-1-pyrophosphate
- anserina
- 1-pyrophosphate
- 5-fluorouridine
-
pyrophosphorolysis
- medicine
- diagnostics
The taxonomic range for the selected organisms is: Homo sapiens
The enzyme appears in selected viruses and cellular organisms
The enzyme appears in selected viruses and cellular organisms
Reaction Schemes
Synonyms
oprt, orotate phosphoribosyltransferase, oprtase, orotate phosphoribosyl transferase, orotidine monophosphate pyrophosphorylase, omp synthase, type i phosphoribosyltransferase, orotidine-5'-phosphate pyrophosphorylase, orotic acid phosphoribosyltransferase, orotidylic acid pyrophosphorylase, 
more
topSYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
OPRT
OPRTase
-
-
-
-
orotate phosphoribosyl pyrophosphate transferase
-
-
-
-
orotate phosphoribosyltransferase
orotate PRTase
-
-
-
-
orotic acid phosphoribosyltransferase
-
-
-
-
orotidine 5'-monophosphate pyrophosphorylase
orotidine 5'-phosphate pyrophosphorylase
-
-
-
-
orotidine monophosphate pyrophosphorylase
-
-
-
-
orotidine phosphoribosyltransferase
-
-
-
-
orotidine-5'-phosphate pyrophosphorylase
-
-
-
-
orotidylate phosphoribosyltransferase
-
-
-
-
orotidylate pyrophosphorylase
-
-
-
-
orotidylic acid phosphorylase
-
-
-
-
orotidylic acid pyrophosphorylase
-
-
-
-
orotidylic phosphorylase
-
-
-
-
orotidylic pyrophosphorylase
-
-
-
-
phosphoribosyltransferase, orotate
-
-
-
-
additional information
-
enzyme from mammals is a bifunctional polypeptide, it also catalyzes the reaction listed as EC 4.1.1.23
OPRT
-
-
-
-
OPRT
-
-
orotate phosphoribosyltransferase
-
-
-
-
orotidine 5'-monophosphate pyrophosphorylase
-
-
-
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
pentosyl group transfer
-
-
-
-
PATHWAY SOURCE
PATHWAYS
BRENDA
-
-, -, -
SYSTEMATIC NAME
IUBMB Comments
orotidine-5'-phosphate:diphosphate phospho-alpha-D-ribosyl-transferase
The enzyme from higher eukaryotes also catalyses the reaction listed as EC 4.1.1.23, orotidine-5'-phosphate decarboxylase.
CAS REGISTRY NUMBER
COMMENTARY
9030-25-5
-
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
5-fluorouracil + 5-phospho-alpha-D-ribose 1-diphosphate
5-fluorouridine 5'-phosphate + diphosphate
5-fluorouracil + 5-phospho-alpha-D-ribose 1-diphosphate
5-fluorouridine 5'-phosphate + diphosphate
-
-
-
-
?
5-fluorouracil + 5-phospho-alpha-D-ribose 1-diphosphate
5-fluorouridine 5'-phosphate + diphosphate
-
essential enzyme for activation of 5-fluorouracil and its derivatives
-
-
?
5-fluorouracil + 5-phospho-alpha-D-ribose 1-diphosphate
5-fluorouridine 5'-phosphate + diphosphate
-
the activating OPRT and its antagonist the catabolizing dihydropyrimidine dehydrogenase play important roles in 5-fluorouracil metabolism, overview
-
-
?
5-fluorouracil + 5-phospho-alpha-D-ribose 1-diphosphate
5-fluorouridine 5'-phosphate + diphosphate
-
the enzyme is involved in degradation of 5-fluorouracil being the key enzyme related to the first-step activation process of 5-fluorouracil, and possibly predicts chemosensitivity to 5-fluorouracil, overview
-
-
?
5-fluorouracil + 5-phospho-alpha-D-ribose 1-diphosphate
5-fluorouridine 5'-phosphate + diphosphate
-
the enzyme is involved in the de novo biosynthesis of pyrimidine nucleotides, main enzyme involved in phosphoribosylation of 5-fluorouracil, an essential step that leads to tumor growth inhibition
-
-
?
5-fluorouracil + 5-phospho-alpha-D-ribose 1-diphosphate
5-fluorouridine 5'-phosphate + diphosphate
-
the enzyme is involved in the metabolism of 5-fluorouracil, a chemotherapeutic drug in treatment of solid cancers, major pathways of 5-fluorouracil metabolism, overview
-
-
?
orotate + 5-phospho-alpha-D-ribose 1-diphosphate
orotidine 5'-phosphate + diphosphate
-
-
-
-
?
orotate + 5-phospho-alpha-D-ribose 1-diphosphate
orotidine 5'-phosphate + diphosphate
-
final steps in biosynthesis of UMP
-
-
?
orotidine 5'-phosphate + diphosphate
orotate + 5-phospho-alpha-D-ribose 1-diphosphate
-
-
-
-
?
orotidine 5'-phosphate + diphosphate
orotate + 5-phospho-alpha-D-ribose 1-diphosphate
-
-
-
-
r
additional information
?
-
-
enzyme from mammals is a bifunctional polypeptide, it also catalyzes the reaction listed as EC 4.1.1.23
-
-
?
additional information
?
-
-
relationship between OPRT, antagonizing dihydropyrimidine dehydrogenase, and clinicopathologic features in cancer and treatment with 5-fluorouracil, relation of patients survival and enzyme activities after surgery, detailed overview
-
-
?
additional information
?
-
-
the enzyme expression is weakly correlated to 5-fluorouracil sensitivity and apoptotic cell rate, overview
-
-
?
additional information
?
-
-
the enzyme is associated with thymidylate synthase and dihydropyrimidine dehydrogenase in resectable colorectal cancer, overview, prognostic impact of the enzyme among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy, overview
-
-
?
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
5-fluorouracil + 5-phospho-alpha-D-ribose 1-diphosphate
5-fluorouridine 5'-phosphate + diphosphate
5-fluorouracil + 5-phospho-alpha-D-ribose 1-diphosphate
5-fluorouridine 5'-phosphate + diphosphate
-
-
-
-
?
5-fluorouracil + 5-phospho-alpha-D-ribose 1-diphosphate
5-fluorouridine 5'-phosphate + diphosphate
-
essential enzyme for activation of 5-fluorouracil and its derivatives
-
-
?
5-fluorouracil + 5-phospho-alpha-D-ribose 1-diphosphate
5-fluorouridine 5'-phosphate + diphosphate
-
the activating OPRT and its antagonist the catabolizing dihydropyrimidine dehydrogenase play important roles in 5-fluorouracil metabolism, overview
-
-
?
5-fluorouracil + 5-phospho-alpha-D-ribose 1-diphosphate
5-fluorouridine 5'-phosphate + diphosphate
-
the enzyme is involved in degradation of 5-fluorouracil being the key enzyme related to the first-step activation process of 5-fluorouracil, and possibly predicts chemosensitivity to 5-fluorouracil, overview
-
-
?
5-fluorouracil + 5-phospho-alpha-D-ribose 1-diphosphate
5-fluorouridine 5'-phosphate + diphosphate
-
the enzyme is involved in the de novo biosynthesis of pyrimidine nucleotides, main enzyme involved in phosphoribosylation of 5-fluorouracil, an essential step that leads to tumor growth inhibition
-
-
?
5-fluorouracil + 5-phospho-alpha-D-ribose 1-diphosphate
5-fluorouridine 5'-phosphate + diphosphate
-
the enzyme is involved in the metabolism of 5-fluorouracil, a chemotherapeutic drug in treatment of solid cancers, major pathways of 5-fluorouracil metabolism, overview
-
-
?
orotate + 5-phospho-alpha-D-ribose 1-diphosphate
orotidine 5'-phosphate + diphosphate
-
-
-
-
?
orotate + 5-phospho-alpha-D-ribose 1-diphosphate
orotidine 5'-phosphate + diphosphate
-
final steps in biosynthesis of UMP
-
-
?
additional information
?
-
-
relationship between OPRT, antagonizing dihydropyrimidine dehydrogenase, and clinicopathologic features in cancer and treatment with 5-fluorouracil, relation of patients survival and enzyme activities after surgery, detailed overview
-
-
?
additional information
?
-
-
the enzyme expression is weakly correlated to 5-fluorouracil sensitivity and apoptotic cell rate, overview
-
-
?
additional information
?
-
-
the enzyme is associated with thymidylate synthase and dihydropyrimidine dehydrogenase in resectable colorectal cancer, overview, prognostic impact of the enzyme among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy, overview
-
-
?
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Mg2+
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(1R,3R,4R)-3-hydroxy-4-(hydroxymethyl)-1-[(4-nitrophenyl)methyl]pyrrolidin-1-ium
-
-
(1S,3R,4R)-3-hydroxy-4-(hydroxymethyl)-1-[2-(4-nitrophenyl)ethyl]pyrrolidin-1-ium
-
-
(2R,3R,4S)-1-[2-(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethyl]-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-ium
-
-
(2R,3R,4S)-1-[2-(6-carboxy-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethyl]-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-ium
-
-
(2S,3S,4R,5R)-2-[(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-1-ium
-
-
(2S,3S,4R,5R)-2-[(6-cyano-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-1-ium
-
-
(3R,4R)-1-[(6-carboxy-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-ium
-
-
(3R,4R)-1-[2-(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-ium
-
-
(7R,8R,9S,9aS)-8,9-dihydroxy-7-(hydroxymethyl)-8,9,9a,10-tetrahydro-7H-pyrrolo[1',2':4,5]pyrazino[1,2-c]pyrimidine-1,3,5(2H)-trione
-
-
1-[(6-carboxy-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl]pyrrolidin-1-ium
-
-
p-nitrophenyl beta-D-ribose 5'-phosphate
-
competitive inhibitor against orotidine 5'-phosphate
[(2R,3R,4S,5S)-5-(4-carboxypyridin-3-yl)-3,4-dihydroxypyrrolidin-1-ium-2-yl]methyl hydrogen phosphate
-
-
[(2R,3R,4S,5S)-5-[(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-3,4-dihydroxypyrrolidin-1-ium-2-yl]methyl hydrogen phosphate
-
-
[(2R,3R,4S,5S)-5-[(6-cyano-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-3,4-dihydroxypyrrolidin-1-ium-2-yl]methyl hydrogen phosphate
-
-
[(3R,4R)-1-[(6-carboxy-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl]-4-hydroxypyrrolidin-1-ium-3-yl]methyl hydrogen phosphate
-
-
[(7R,8R,9S,9aS)-8,9-dihydroxy-1,3,5-trioxo-1,2,3,5,8,9,9a,10-octahydro-7H-pyrrolo[1',2':4,5]pyrazino[1,2-c]pyrimidin-7-yl]methyl hydrogen phosphate
-
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.091
Orotidine
-
pH not specified in the publication, temperature not specified in the publication
0.00155
orotidine 5'-phosphate
-
in the presence of 1 mM diphosphate, at 25°C, 50 mM Tris-HCl, pH 8.0, 5 mM MgCl2
0.0016
orotidine 5'-phosphate
-
pH not specified in the publication, temperature not specified in the publication
0.00214
orotidine 5'-phosphate
-
in the presence of 20 mM phosphonoacetic acid, at 25°C, 50 mM Tris-HCl, pH 8.0, 5 mM MgCl2
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.017
orotidine 5'-phosphate
-
in the presence of 20 mM phosphonoacetic acid, at 25°C, 50 mM Tris-HCl, pH 8.0, 5 mM MgCl2
0.1
orotidine 5'-phosphate
-
in the presence of 1 mM diphosphate, at 25°C, 50 mM Tris-HCl, pH 8.0, 5 mM MgCl2
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
7.9
orotidine 5'-phosphate
-
in the presence of 20 mM phosphonoacetic acid, at 25°C, 50 mM Tris-HCl, pH 8.0, 5 mM MgCl2
65
orotidine 5'-phosphate
-
in the presence of 1 mM diphosphate, at 25°C, 50 mM Tris-HCl, pH 8.0, 5 mM MgCl2
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.2
(1R,3R,4R)-3-hydroxy-4-(hydroxymethyl)-1-[(4-nitrophenyl)methyl]pyrrolidin-1-ium
-
at pH 8.0 and 25°C
0.23
(1S,3R,4R)-3-hydroxy-4-(hydroxymethyl)-1-[2-(4-nitrophenyl)ethyl]pyrrolidin-1-ium
-
at pH 8.0 and 25°C
0.08
(2R,3R,4S)-1-[2-(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethyl]-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-ium
-
at pH 8.0 and 25°C
0.29
(2R,3R,4S)-1-[2-(6-carboxy-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethyl]-3,4-dihydroxy-2-(hydroxymethyl)pyrrolidin-1-ium
-
at pH 8.0 and 25°C
0.23
(2R,3S)-3-hydroxy-2-(hydroxymethyl)-5-(4-nitrophenyl)pyrrolidin-1-ium
-
at pH 8.0 and 25°C
0.53
(2S,3S,4R,5R)-2-[(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-1-ium
-
at pH 8.0 and 25°C
0.36
(2S,3S,4R,5R)-2-[(6-cyano-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-1-ium
-
at pH 8.0 and 25°C
0.083
(3R,4R)-1-[(6-carboxy-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-ium
-
at pH 8.0 and 25°C
0.52
(3R,4R)-1-[2-(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-ium
-
at pH 8.0 and 25°C
0.11
(7R,8R,9S,9aS)-8,9-dihydroxy-7-(hydroxymethyl)-8,9,9a,10-tetrahydro-7H-pyrrolo[1',2':4,5]pyrazino[1,2-c]pyrimidine-1,3,5(2H)-trione
-
at pH 8.0 and 25°C
0.15
1,3-dihydroxy-N-[(4-nitrophenyl)methyl]propan-2-aminium
-
at pH 8.0 and 25°C
0.12
1,3-dihydroxy-N-[2-(4-nitrophenyl)ethyl]propan-2-aminium
-
at pH 8.0 and 25°C
0.25
1-[(6-carboxy-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl]pyrrolidin-1-ium
-
at pH 8.0 and 25°C
0.000121
p-nitrophenyl beta-D-ribose
-
in the presence of orotidine 5'-phosphate, at 25°C, 50 mM Tris-HCl, pH 8.0, 5 mM MgCl2
0.000041
p-nitrophenyl beta-D-ribose 5'-phosphate
-
in the presence of orotidine 5'-phosphate, at 25°C, 50 mM Tris-HCl, pH 8.0, 5 mM MgCl2
4.3
[(2R,3R,4S,5S)-5-(4-carboxypyridin-3-yl)-3,4-dihydroxypyrrolidin-1-ium-2-yl]methyl hydrogen phosphate
-
at pH 8.0 and 25°C
0.2
[(2R,3R,4S,5S)-5-[(5-bromo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-3,4-dihydroxypyrrolidin-1-ium-2-yl]methyl hydrogen phosphate
-
at pH 8.0 and 25°C
0.14
[(2R,3R,4S,5S)-5-[(6-cyano-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-3,4-dihydroxypyrrolidin-1-ium-2-yl]methyl hydrogen phosphate
-
at pH 8.0 and 25°C
0.24
[(3R,4R)-1-[(6-carboxy-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl]-4-hydroxypyrrolidin-1-ium-3-yl]methyl hydrogen phosphate
-
at pH 8.0 and 25°C
0.09
[(7R,8R,9S,9aS)-8,9-dihydroxy-1,3,5-trioxo-1,2,3,5,8,9,9a,10-octahydro-7H-pyrrolo[1',2':4,5]pyrazino[1,2-c]pyrimidin-7-yl]methyl hydrogen phosphate
-
at pH 8.0 and 25°C
10.8
sulfate
-
orotidine 5'-phosphate as substrate, pH not specified in the publication, temperature not specified in the publication
17.6
sulfate
-
orotidine 5'-phosphate as substrate, pH not specified in the publication, temperature not specified in the publication
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
additional information
-
ELISA assay method development and evaluation for enzyme detection and quantification in cancer tissue, overview
additional information
-
enzyme expression rate in tumor tissue with or without treatment with 5-fluorouracil
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
-
in normal non-neoplastic colorectal epithelium, granular staining is observed only in the crypt
-
in gallbladder carcinoma, mucosal neoplastic epithelium shows dense cytoplasmic expression but expression is absent in the deeply invasive lesions
-
mucosal neoplastic epithelium, granular expression
-
OPRT is involved in early events of invasion of hepatocellular carcinoma cells
-
normal tissue, hormone-sensitive prostate cancer (HSPC) or hormonerefractory prostate cancer (HRPC) tissue
-
gastric cancer cell line with low baseline expression levels of OPRT
additional information
-
colorectal cancer, 150 patients with cancer at different stages, stage-related enzyme expression level, overview
-
221 specimen, expression profile of the enzyme and its antagonist dihydropyrimidine dehydrogenase both active in 5-fluorouracil metabolism, the enzyme expression levels correlate, overview
-
OPRT levels are high in well differentiated and localized gastric carcinomas and are significantly higher in gastric carcinoma tissue than in normal gastric mucosa
-
gastric cancer cell line with low baseline expression levels of OPRT
-
OPRT is involved in early events of pancreatic carcinogenesis
additional information
-
expression analysis in carcinoma cell lines, no expression in pancreatic ducts and PanIN-1A cells, overview
additional information
-
the enzyme expression is increased in tumor tissue compared to non-tumor tissue
additional information
-
in mucosal carcinoma lesions frequency of OPRT expression is 32.1%, in infiltrative lesions frequency of OPRT expression is 69.8%. In lymphovascularly invasive lesions frequency of OPRT expression is 88.2% and in metastatic lymph nodes frequency of OPRT expression is 88.8%
additional information
-
MKN-45/F2R cell, 5-fluorouracil resistant gastric cancer cell line
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
malfunction
-
decreased activity of OPRT plays an important role in the acquired resistance of gastric cancer cells towards 5-fluorouracil. OPRT-knockout MKN-45 parent cells using small interfering RNA demonstrate 15.8fold increased resistance to 5-fluorouracil compared to the control cell
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). UMPS_HUMAN
480
0
52222
Swiss-Prot
other Location (Reliability: 4)
A8K5J1_HUMAN
480
0
52222
TrEMBL
other Location (Reliability: 4)
B5LY71_HUMAN
480
0
52277
TrEMBL
other Location (Reliability: 4)
B5LY69_HUMAN
374
0
40254
TrEMBL
other Location (Reliability: 4)
PDB
SCOP
CATH
UNIPROT
ORGANISM
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
52000
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
G213A
-
OPRT, the gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen, the Ala allele in the enzyme G213A polymorphism and the two tandem repeats in the TYMS promoter polymorphism are associated with grade 3 to 4 neutropenia and diarrhea, distribution in 69 patients samples, genotyping, relationship between OPRT mRNA expression and the OPRT G213A polymorphism, overview
additional information
-
mutational separation of catalytic activity of enzyme and EC4.1.1.23 activity results in active but unstable proteins
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
OPRT, stable overexpression in the gastric cancer cell lines TMK-1 and MKN-45, enhancing the effect of 5-fluorouracil on the cells, transfected cells show a similar growth curve as the wild-type parent cells, while the drug sensitivity is increased compared to the untransfected cells, overview
-
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
enzyme expression is extremely high in malignant pleural mesothelioma tumor tissue
-
lexpression of OPRT in mucosal carcinoma components, in infiltrative components, in lymphovascularly invasive lesions and in metastatic lymph nodes. No significant correlation between OPRT expression and cancer stage, T-grade or N-grade, but OPRT expression correlates positively with the presence of lymphovascular invasion. OPRT is diffusely expressed to a greater extent, especially in the tumor cells adjacent to the infiltrative margin
-
mRNA expression of OPRT is markedly decreased to 12.4% and activity to 46.9% in the 5-fluorouracil resistant MKN-45/F2R cell line compared to the MKN-45 parent cell line. OPRT gene expression is markedly decreased to 14.4% when down-regulated by siRNA
-
strong expression of OPRT in prostate cancer cells, significant correlation between OPRT mRNA expression levels and the tumor pathological grade. The OPRT/dihydropyrimidine dehydrogenase expression ratio in the HRPC group is significantly higher than that in the low grade HSPC group
-
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
diagnostics
medicine
diagnostics
-
OPRT activity in tumor tissue is a predictor of prognosis in resectable CRC patients treated by oral 5-fluorouracil-based adjuvant chemotherapy, and is useful to pick-up high risk patients independent from known prognosis factors
medicine
-
enzyme activity is 7.5fold enhanced in bladder carcinoma compared to normal. Bladder carcinoma subtypes show distinct levels of enzyme activity and there is positive association between the activity levels of enzyme and thymidylate synthase/thymidine kinase. Enzyme activity in bladder carcinoma cells also correlates positively with their sensitivity to 5-fluorouracil
medicine
-
immunochemical detection of tumoral enzyme expression by antibody, method for predicting the clinical response to 5-fluorouracil-based chemotherapy
medicine
-
OPRT activity is significantly lower in tumors with lymph node metastasis than in tumors lacking lymph node metastasis, thus OPRT activity level in tumor tissue may be an important prognostic factor for survival in Dukes B and C colorectal carcinoma cells with radical resection and adjuvant chemotherapy with orally administered tegafur/uracil
medicine
-
OPRT expression is negatively associated with colorectal cancer progression
medicine
-
the expression of OPRT may be useful to predict the response to adjuvant chemotherapy with 5-fluorouracil in human pancreatic cancer
medicine
-
the OPRT mRNA level is positively correlated with the 5-fluorouracil efficacy in antitumor therapy
medicine
-
the enzyme is used as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients. Cholangiocarcinoma patients with high enzyme expression can benefit from postoperative adjuvant S-1 therapy, which increases the disease-free survival
medicine
-
the expression of the enzyme shows no association with the overall survival or diseasex1efree survival, even in the patients who receive Sx1e1 adjuvant chemotherapy
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Yablonski, M.J.; Pasek, D.A.; Han, B.D.; Jones, M.E.; Traut, T.W.
Intrinsic activity and stability of bifunctional human UMP synthase and its two separate catalytic domains, orotate phosphoribosyltransferase and orotidine-5'-phosphate decarboxylase
J. Biol. Chem.
271
10704-10708
1996
Homo sapiens
Rathod, P.K.; Reyes, P.
Orotidylate-metabolizing enzymes of the human malarial parasite, Plasmodium falciparum, differ from host cell enzymes
J. Biol. Chem.
258
2852-2855
1983
Homo sapiens, Plasmodium falciparum, Plasmodium falciparum FCB
Krungkrai, J.; Wutipraditkul, N.; Prapunwattana, P.; Krungkrai, S.R.; Rochanakij, S.
A nonradioactive high-performance liquid chromatographic microassay for uridine 5'-monophosphate synthase, orotate phosphoribosyltransferase, and orotidine 5'-monophosphate decarboxylase
Anal. Biochem.
299
162-168
2001
Homo sapiens, Mus musculus
Mizutani, Y.; Wada, H.; Fukushima, M.; Yoshida, O.; Nakanishi, H.; Li, Y.N.; Miki, T.
Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma
Cancer
100
723-731
2004
Homo sapiens
Sakamoto, K.; Sugimoto, Y.; Miyadera, K.; Oka, T.; Fukushima, M.
Preparation of anti-orotate phosphoribosyltransferase antibody and its application to immunochemical detection in human tumor cells
Int. J. Mol. Med.
16
245-249
2005
Homo sapiens
Sakurai, Y.; Sakamoto, K.; Sugimoto, Y.; Yoshida, I.; Masui, T.; Tonomura, S.; Inaba, K.; Shoji, M.; Nakamura, Y.; Uyama, I.; Komori, Y.; Ochiai, M.; Matsuura, S.; Tanaka, H.; Oka, T.; Fukushima, M.
Orotate phosphoribosyltransferase levels measured by a newly established enzyme-linked immunosorbent assay in gastric carcinoma
Cancer Sci.
97
492-498
2006
Homo sapiens
Matsusaka, S.; Yamasaki, H.; Fukushima, M.; Wakabayashi, I.
Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer
Chemotherapy
53
36-41
2007
Homo sapiens
Ichikawa, W.; Takahashi, T.; Suto, K.; Sasaki, Y.; Hirayama, R.
Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen
Clin. Cancer Res.
12
3928-3934
2006
Homo sapiens
Ochiai, T.; Nishimura, K.; Noguchi, H.; Kitajima, M.; Tsukada, A.; Watanabe, E.; Nagaoka, I.; Futagawa, S.
Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy
Int. J. Cancer
118
3084-3088
2006
Homo sapiens
Kawai, K.; Watabe, S.; Matsuda, M.; Sakamoto, K.; Kamano, T.
Correlation between expression of orotate phosphoribosyl transferase and 5-fluorouracil sensitivity, as measured by apoptosis index in colorectal cancer tissue
Int. J. Gastrointest. Cancer
35
197-203
2005
Homo sapiens
Oeda, M.; Yoshida, K.; Sanada, Y.; Wada, Y.; Suzuki, T.; Mizuiri, H.; Konishi, K.; Shigematsu, H.; Tanabe, K.; Fukushima, M.
The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance
Oncol. Rep.
16
1165-1172
2006
Homo sapiens
Taomoto, J.; Yoshida, K.; Wada, Y.; Tanabe, K.; Konishi, K.; Tahara, H.; Fukushima, M.
Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-fluorouracil on gastric cancer cell lines
Oncology
70
458-464
2006
Homo sapiens
Sanada, Y.; Yoshida, K.; Ohara, M.; Tsutani, Y.
Expression of orotate phosphoribosyltransferase (OPRT) in hepatobiliary and pancreatic carcinoma
Pathol. Oncol. Res.
13
105-113
2007
Homo sapiens
Tokunaga, Y.; Sasaki, H.; Saito, T.
Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine
Surgery
141
346-353
2007
Homo sapiens
Ogiuchi, Y.; Maruoka, Y.; Ando, T.; Kobayashi, M.; Ogiuchi, H.
Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma
Acta Histochem. Cytochem.
41
39-46
2008
Homo sapiens
Sakamoto, E.; Nagase, H.; Kobunai, T.; Oie, S.; Oka, T.; Fukushima, M.; Oka, T.
Orotate phosphoribosyltransferase expression level in tumors is a potential determinant of the efficacy of 5-fluorouracil
Biochem. Biophys. Res. Commun.
363
216-222
2007
Homo sapiens
Ishikawa, M.; Miyauchi, T.; Kashiwagi, Y.
Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activity levels in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapy
BMC Cancer
8
188
2008
Homo sapiens
Kai, K.; Kitajima, Y.; Hiraki, M.; Satoh, S.; Tanaka, M.; Nakafusa, Y.; Tokunaga, O.; Miyazaki, K.
Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens
Cancer Lett.
258
45-54
2007
Homo sapiens
Sakurai, Y.; Kamoshida, S.; Furuta, S.; Sunagawa, R.; Inaba, K.; Isogaki, J.; Komori, Y.; Uyama, I.; Tsutsumi, Y.
Levels and expressions of orotate phosphoribosyltransferase in gastric carcinoma and normal gastric mucosa tissues
Gastric Cancer
10
234-240
2007
Homo sapiens
Miyake, K.; Imura, S.; Yoshizumi, T.; Ikemoto, T.; Morine, Y.; Shimada, M.
Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer
Int. J. Clin. Oncol.
12
111-119
2007
Homo sapiens
Nio, Y.; Toga, T.; Maruyama, R.; Fukushima, M.
Expression of orotate phosphoribosyl transferase in human pancreatic cancer: implication for the efficacy of uracil and tegafur-based adjuvant chemotherapy
Oncol. Rep.
18
59-64
2007
Homo sapiens
Zhang, Y.; Luo, M.; Schramm, V.L.
Transition states of Plasmodium falciparum and human orotate phosphoribosyltransferases
J. Am. Chem. Soc.
131
4685-4694
2009
Homo sapiens, Plasmodium falciparum
Sanada, Y.; Yoshida, K.; Hihara, J.; Okada, M.
Expression of orotate phosphoribosyltransferase in colorectal carcinoma: an immunohistochemical analysis in several components of neoplastic lesions
Oncol. Rep.
20
1005-1011
2008
Homo sapiens
Tsutani, Y.; Yoshida, K.; Sanada, Y.; Wada, Y.; Konishi, K.; Fukushima, M.; Okada, M.
Decreased orotate phosphoribosyltransferase activity produces 5-fluorouracil resistance in a human gastric cancer cell line
Oncol. Rep.
20
1545-1551
2008
Homo sapiens
Tanaka, T.; Kawashima, H.; Matsumura, K.; Yamashita-Hosono, T.; Yoshimura, R.; Kuratsukuri, K.; Harimoto, K.; Nakatani, T.
Overexpression of orotate phosphoribosyl transferase in hormone-refractory prostate cancer
Oncol. Rep.
21
33-37
2009
Homo sapiens
Zhang, Y.; Schramm, V.
Ground-state destabilization in orotate phosphoribosyltransferases by binding isotope effects
Biochemistry
50
4813-4818
2011
Homo sapiens, Plasmodium falciparum
Zhang, Y.; Schramm, V.
Pyrophosphate interactions at the transition states of plasmodium falciparum and human orotate phosphoribosyltransferases
J. Am. Chem. Soc.
132
8787-8794
2010
Homo sapiens, Plasmodium falciparum
Hozumi, Y.; Tanaka, T.; Nakano, T.; Matsui, H.; Nasu, T.; Koike, S.; Kakehata, S.; Ito, T.; Goto, K.
Orotate phosphoribosyltransferase localizes to the Golgi complex and its expression levels affect the sensitivity to anti-cancer drug 5-fluorouracil
Biomed. Res.
36
403-409
2015
Homo sapiens
Zhang, Y.; Evans, G.B.; Clinch, K.; Crump, D.R.; Harris, L.D.; Froehlich, R.F.; Tyler, P.C.; Hazleton, K.Z.; Cassera, M.B.; Schramm, V.L.
Transition state analogues of Plasmodium falciparum and human orotate phosphoribosyltransferases
J. Biol. Chem.
288
34746-34754
2013
Homo sapiens, Plasmodium falciparum
Akahoshi, K.; Ban, D.; Kuboki, R.; Oba, A.; Ono, H.; Mitsunori, Y.; Kudo, A.; Tanaka, S.; Tanabe, M.
Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients
J. Gastroenterol. Hepatol.
34
1108-1115
2019
Homo sapiens
Okuda, K.; Tatematsu, T.; Yano, M.; Nakamae, K.; Yamada, T.; Kasugai, T.; Nishida, T.; Sano, M.; Moriyama, S.; Haneda, H.; Kawano, O.; Sakane, T.; Oda, R.; Watanabe, T.; Nakanishi, R.
The relationship between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, excision repair cross-complementation group 1 and class III beta-tubulin, and the therapeutic effect of S-1 or carboplatin plus paclitaxel in nonx1esmallx1ecell lung cancer
Mol. Clin. Oncol.
9
21-29
2018
Homo sapiens
Hamamoto, Y.; Takeoka, S.; Mouri, A.; Fukusumi, M.; Wakuda, K.; Ibe, T.; Honma, C.; Arimoto, Y.; Yamada, K.; Wagatsuma, M.; Tashiro, A.; Kamoshida, S.; Kamimura, M.
Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma Dramatically responds one case in high OPRT expression
Rare Dis.
4
e1165909
2016
Homo sapiens
EXTERNAL LINKS (specific for EC-Number 2.4.2.10)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
